Green Shield Canada invests in GenXys to harness power of pharmacogenomics

June 4, 2020

On May 26, 2020, Green Shield Canada, our lead investor and a major health and dental benefits provider, issued a press release announcing their investment in GenXys along with a recent very positive pharmacogenetics study they are publishing. This is all in the context of growing momentum of personalized medicine. They had delayed their investment announcement to coincide with their PGx clinical study announcement. The study and its exceptionally positive clinical outcomes will be published in a highly regarded medical journal later this summer. Here is the GSC 

Press Release